AKT1 and breast neoplasm: Several clinical studies have been focused on the modulation of phosphoinositide 3-kinase (PI3K)/Akt/mTOR pathway to overcome chemotherapy or hormonotherapy resistance in breast tumors such as everolimus (37) or temsirolimus (38); this intricated pathway is not yet fully understood and need more studies (39).